Home

Darren S Cline

CIK 1633639 · Chief Commercial Officer · last filed 2026-06-12

Darren S Cline is a Chief Commercial Officer who has filed 52 SEC Form 4 insider transactions across 7 companies since 2015. The most recent filing, for PLRX, was dated Jun 12, 2026. Across all open-market trades the lifetime net is −$5.4M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $731.6K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$731.6K

Companies

7

Total Filings

52

Lifetime Open-Market Net

-$5.37M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
PLRX Director — $1.07 — $0 5 2026-06-12
PYXS Director 251,405 $2.91 $731.6K $93.9K 7 2026-03-25
XENE Chief Commercial Officer — $64.94 — $0 2 2026-01-09
IPI Legacy Liquidation Co (IMPL) Delisted Director — $0.24 — $0 2 2023-06-20
GW PHARMACEUTICALS PLC (GWPH) Delisted U.S. Chief Commercial Officer 5,556 $218.96 $1.22M $0 5 2021-03-04
STEMLINE THERAPEUTICS INC (STML) Delisted Director 0 — — $0 3 2020-06-10
Seagen Inc. (SGEN) Delisted EVP, Commercial 72,556 $228.74 $16.60M -$5.46M 27 2018-11-30

Recent Filings

52 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-12 PLRX Grant (A) — $0 EDGAR
2026-03-25 PYXS Grant (A) — $0 EDGAR
2026-01-09 XENE Grant (A) — $0 EDGAR
2025-06-24 XENE Grant (A) — $0 EDGAR
2025-06-09 PLRX Grant (A) — $0 EDGAR
2025-04-02 PYXS Grant (A) — $0 EDGAR
2024-06-17 PLRX Grant (A) — $0 EDGAR
2024-03-28 PYXS Grant (A) +35,219 $0 EDGAR
2023-06-20 IPI Legacy Liquidation Co (IMPL) Delisted Grant (A) — $0 EDGAR
2023-06-08 PLRX Grant (A) — $0 EDGAR
Showing 1–10 of 52
Page 1 of 6
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.